Collaboration with pharmaceutical industry for the development of novel therapeutics for the treatment of diabetes
| Reference number | |
| Coordinator | Lunds universitet - Institutionen för experimentell medicinsk vetenskap, Lund |
| Funding from Vinnova | SEK 25 210 |
| Project duration | February 2015 - March 2015 |
| Status | Completed |
Purpose and goal
Lund University Diabetes Center (LUDC) is a world leader in fundamental research in diabetes diseases. Drug development is a complex and expensive process where academia and the pharmaceutical industry more effectively need to work together. A researcher at LUDC aims to further develop his knowledge in drug development and to strengthen innovation at LUDC. The exchange program is part of ongoing cooperations with pharmaceutical companies. The planning grant was sought to finance visits at these companies.
Results and expected effects
The exchange is expected to provide a major impact in several areas. A main objective of the VINNMER project is to strengthen the candidate´s skills and networks within the pharmaceutical industry, and to initiate and strengthen important contacts between Lund University and the global pharmaceutical companies. The planning grant has enabled the involved parties to jointly formulate the conditions for long-term and successful cooperative exchange.
Approach and implementation
The planning of the VINNMER application is done together with international pharmaceutical companies in Europe and North America and has included visits at the company sites. In addition, LUDC and LUDC Innovation, the management at Faculty of Medicine, as well as the vice-Chancellor of have been active in the planning stage. Visits to the companies was carried out as planned and have resulted in the completion of a full VINNMER application that was submitted in March 2015.